Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd

Link copied
Case Copied 71 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239

Citation: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239
Parties: OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY v GENERIC HEALTH PTY LTD (ACN 110 617 859)
File number(s): NSD 121 of 2012
Judge: YATES J
Date of judgment: 16 March 2012
Catchwords:

PATENTS – application for interlocutory injunctions – threatened supply of generic pharmaceutical products – imminent listing of products in the Pharmaceutical Benefits Scheme Schedule – whether prima facie case of infringement – whether balance of convenience and justice favours the grant of interlocutory injunctive relief – whether undertakings should be accepted in lieu of interlocutory injunctive relief

PATENTS – discussion of meaning of “exploit” as used in s 13 of the Patents Act 1990 (Cth) – “Swiss-style” claims – discussion whether claimed invention is a method or process

PATENTS – method of treatment claims – infringement by supply – discussion whether generic pharmaceutical product a staple commercial product – whether instructions or inducement given to use the product in a claimed method of treatment

PATENTS – “Gillette defence” – discussion whether a separate and discrete defence under the Patents Act 1990 (Cth)

Legislation: Patents Act 1990 (Cth) ss 7, 13, 18, 117, 138 and Sch 1
Cases cited: Aktiebolaget Hassle v Biochemie Australia Pty Ltd (2003) 57 IPR 1
Appleton Papers Inc v Tomasetti Paper Pty Ltd [1983] 3 NSWLR 208
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [1999] RPC 253
Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [2001] RPC 1
Castlemaine Tooheys Ltd v South Australia (1986) 161 CLR 148
Eli Lilly Canada Inc v Apotex Inc and the Minister of Health (2008) 75 IPR 625
Gillette Safety Razor Company v Anglo-American Trading Company Ld (1913) 30 RPC 465
Hexal Australia Pty Ltd v Roche Therapeutics Inc (2005) 66 IPR 325
Interpharma Pty Ltd v Commissioner of Patents (2008) 79 IPR 261
John Wyeth & Brother Ltd’s Application [1985] RPC 545
McCarty v The Council of the Municipality of North Sydney (1918) 18 SR (NSW) 210
Northern Territory v Collins (2008) 235 CLR 619
Pharmaceutical Management Agency Ltd v Commissioner of Patents [2000] 2 NZLR 529
Pharmacia Italia SpA v Interpharma Pty Ltd (2005) 67 IPR 397
R v MacFarlane;  Ex Parte O’Flanagan and O’Kelly (1923) 32 CLR 518
Re Eisai’s Application – Second Medical Indication [1985] OJ EPO 64 
Samsung Electronics Co Limited v Apple Inc [2011] FCAFC 156
Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) (2011) 196 FCR 1
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2009) 81 IPR 339
Tidy Tea Ltd & Lyons Tetley Ltd v Unilever Australia Ltd (1995) 32 IPR 405
Woodbridge Foam Corporation v AFCO Automotive Foam Components Pty Ltd (2002) 58 IPR 56
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FCA 239
Decision Date

CaseChat Overview and Summary

Otsuka Pharmaceutical Co Ltd sought interlocutory injunctions against Generic Health Pty Ltd, over the supply of generic pharmaceutical products for the treatment of schizophrenia. The matter was heard in the Federal Court of Australia. The applicants, Otsuka Pharmaceutical, alleged that the respondents’ products infringed their patent rights. The respondents planned to supply their products in competition with the applicants’ patented products, which were listed in the Pharmaceutical Benefits Scheme Schedule.

The legal issues before the court included whether there was a prima facie case of patent infringement, and whether the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court also considered whether certain undertakings offered by the respondents could be accepted in lieu of interlocutory injunctive relief. The meaning of "exploit" as used in section 13 of the Patents Act 1990 (Cth) was also discussed, as was whether the claimed invention was a method or process. The court further considered whether the generic pharmaceutical product was a staple commercial product and whether instructions or inducements were given to use the product in a claimed method of treatment. The "Gillette defence" was also discussed as a possible defence under the Patents Act 1990 (Cth).

The court found that there was a prima facie case of patent infringement, and that the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court held that the meaning of "exploit" in section 13 of the Patents Act 1990 (Cth) encompassed the commercial manufacture, use or sale of a patented invention. The court found that the claimed invention was a method or process for the treatment of schizophrenia, and that the generic pharmaceutical product was not a staple commercial product. The court also held that the respondents had given instructions or inducements to use the product in a claimed method of treatment, and that the "Gillette defence" was not a separate and discrete defence under the Patents Act 1990 (Cth). The court ultimately found that the respondents’ undertakings were not acceptable, and granted the interlocutory injunctions sought by the applicants.

The final orders of the court required the parties to bring in draft orders giving effect to the reasons of the court.

Orders

Orders of the court

1. The parties are to bring in draft orders giving effect to these reasons.

Background

Background to the litigation

Following the hearing for interim relief, the respondent offered a further undertaking to the Court. This undertaking relates to the manner in which the GH products will be marketed pending the hearing of the applicants’ claims for final relief. This undertaking is not acceptable to the applicants. The respondent intends to pursue its plans to import and supply its GH products in competition with the Abilify products. BACKGROUNDSchizophrenia and its treatment Schizophrenia is a serious mental disorder affecting 1% of the population worldwide. It generally comes on in early adulthood. Its main features are disturbances in the ability to experience reality, lack of capacity to engage with others in the outside world, and disturbances in thinking, behaviour and emotional responses. The disorder may run a number of courses, but standard definitions of schizophrenia state that the symptoms must last for at least 6 months for the diagnosis to be made. The condition is chronic in a majority of cases. Its cause is not known. The symptoms of schizophrenia can be classified into a number of separate dimensions. Generally speaking, the four main dimensions of classification are (a) positive symptoms; (b) negative symptoms; (c) cognitive symptoms; and (d) mood symptoms. These dimensions are not universally defined in precisely the same way. For example, some consider cognitive impairment or cognitive symptoms to fall within the category of negative symptoms, while others consider that cognitive impairment constitutes a totally separate symptom category. The positive symptoms of schizophrenia include hallucinations (that is, the perception of a sensory experience in the absence of a source) and delusions (that is, fixed false beliefs not shared by others). The negative symptoms of schizophrenia include the blunting of emotional response, apathy, amotivation and poverty of thinking. The mood symptoms of schizophrenia include anxiety and depression. Cognitive impairment refers to a range of impaired higher cognitive functions, including problems with attention, long term memory, and abstraction and planning. The main manifestations of this impairment with schizophrenia are disturbances in attention, memory and executive function (such as the ability to generate and implement plans). A patient suffering from cognitive impairment will generally exhibit difficulty in thinking and in articulating thoughts. These disturbances can be demonstrated on a range of neuropsychological tests. It has been known since schizophrenia was first identified nearly 100 years ago that cognitive deterioration can occur in patients suffering from the illness. It has also been known since the 1970s that schizophrenia is associated with an increase in the size of the cerebral ventricles (the fluid filled spaces in the brain), reflecting the fact that there is a decrease in brain volume which appears to be the basis for these cognitive disturbances. In this sense, cognitive impairment is understood to be an accompaniment of schizophrenia.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.